Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer

Melanoma Research

Volumn 19, Issue 4, 2009, Pages 211-214

  Nagore, Eduardo ^a   Montoro, Alegria ^a   García Casado, Zaida ^a   Botella Estrada, Rafael ^a   Insa, Amelia ^b   Lluch, Ana ^b   López Guerrero, José A ^a   Guillén, Carlos ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Breast cancer; CDKN2A; Cutaneous melanoma

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR;

ADULT; AGED; ARTICLE; BREAST TUMOR; DNA SEQUENCE; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; MELANOMA; MIDDLE AGED; MUTATION; OVARY TUMOR; SECOND CANCER; SKIN TUMOR; SPAIN; TUMOR SUPPRESSOR GENE;

ADP-RIBOSYLATION FACTORS; ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MELANOMA; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; SKIN NEOPLASMS; SPAIN;

EID: 70349916132     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283281057     Document Type: Article

References (21)

1. Goggins W, Gao W, Tsao H. Association between female breast cancer and cutaneous melanoma. Int J Cancer 2004; 111:792-794. (Pubitemid 39062905)
2. Levi F, Te VC, Randimbison L, La Vecchia C. Cancer risk in women with previous breast cancer. Ann Oncol 2003; 14:71-73. (Pubitemid 36150261)
3. Volk N, Pompe-Kirn V. Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control 1997; 8:764-770. (Pubitemid 27404647)
4. Rubino C, de Vathaire F, Diallo I, Shamsaldin A, Le MG. Increased risk of second cancers following breast cancer: role of the initial treatment. Breast Cancer Res Treat 2000; 61:183-195. (Pubitemid 30609552)
5. Wassberg C, Thorn M, Yuen J, Hakulinen T, Ringborg U. Cancer risk in patients with earlier diagnosis of cutaneous melanoma in situ. Int J Cancer 1999; 83:314-317. (Pubitemid 29455753)
6. Ghiorzo P, Ciotti P, Mantelli M, Heouaine A, Queirolo P, Rainero ML, et al. Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 1999; 83:441-448. (Pubitemid 29489856)
7. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. Lancet 2001; 358:1389-1399.
8. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41:2040-2059. (Pubitemid 41337946)
9. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999; 91:1310-1316.
10. Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000; 92:1260-1266. (Pubitemid 30627734)
11. Debniak T, Gorski B, Huzarski T, Byrski T, Cybulski C, Mackiewicz A, et al. A common variant of CDKN2A (p16) predisposes to breast cancer. J Med Genet 2005; 42:763-765. (Pubitemid 41475251)
12. Nagore E, Montoro A, Oltra S, Ledesma E, Botella-Estrada R, Millan JM, et al. Age does not appear to be a major indicator of CDKN2A or CDK4 mutations in melanoma patients in Spain. Melanoma Res 2005; 15:555-558. (Pubitemid 44124269)
13. Nagore E, Oliver V, Botella-Estrada R, Moreno-Picot S, Guillen C, Fortea JM. Clinicopathological analysis of 1571 cutaneous malignant melanomas in Valencia, Spain: factors related to tumour thickness. Acta Derm Venereol 2006; 86:50-56. (Pubitemid 46939789)
14. Debniak T, Scott RJ, Huzarski T, Byrski T, Rozmiarek A, Debniak B, et al. CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res 2005; 65:835-839. (Pubitemid 40216442)
15. Puig S, Malvehy J, Badenas C, Ruiz A, Jimenez D, Cuellar F, et al. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 2005; 23:3043-3051. (Pubitemid 46224126)
16. Spica T, Portela M, Gerard B, Formicone F, Descamps V, Crickx B, et al. The A148T variant of the CDKN2A gene is not associated with melanoma risk in the French and Italian populations. J Invest Dermatol 2006; 126:1657-1660.
17. Bertram CG, Gaut RM, Barrett JH, Pinney E, Whitaker L, Turner F, et al. An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele. J Invest Dermatol 2002; 119:961-965. (Pubitemid 35340925)
18. Yakobson E, Eisenberg S, Isacson R, Halle D, Levy-Lahad E, Catane R, et al. A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families. Eur J Hum Genet 2003; 11:288-296. (Pubitemid 36553487)
19. Monnerat C, Chompret A, Kannengiesser C, Avril MF, Janin N, Spatz A, et al. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma. Fam Cancer 2007; 6: 453-461. (Pubitemid 47622260)
20. Ewertz M, Mouridsen HT. Second cancer following cancer of the female breast in Denmark, 1943-80. Natl Cancer Inst Monogr 1985; 68:325-329. (Pubitemid 16233737)
21. Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985; 68:99-112. (Pubitemid 16233726)